Myasthenia Gravis Treatment Market

Myasthenia Gravis Treatment Market Outlook 2031:

The Global Myasthenia Gravis Treatment Market  size was valued at USD 1.7 Billion in 2022 and is expected to surpass USD 3 Billion by 2031, expanding at a CAGR of 6.5% during the forecast period, 2023 – 2031. The growth of the market is attributed to the growing adoption of rare diseases, approvals for promising drugs, increasing adoption of immunotherapies, and emergence of biologics.

Myasthenia gravis (MG) is rare, chronic, and progressive neuromuscular disorder which causes weakness of the head, eye, limb, respiratory muscles, and spinal. MG is autoimmune disorder in which against the acetylcholine receptor (AchR) antibodies are produced. Myasthenia gravis hampers the normal transmission of electrical signals from nerves to muscles.

Get Free Sample Report

According to the National Organization for Rare Disorders (NORD), approximately 20-35 per 100,000 individuals suffer from myasthenia gravis in the U.S. also, number of disorders are increasing over the last several decades. This is attributed to rising incidence of autoimmune disorders and better identification of patients across the globe.

Myasthenia gravis occurs generally in females than in males. Symptoms of MG appears at any age, but in men it’s appear during their 50s or 60s and in women usually in their 20s or 30s. There is no permanent cure for myasthenia gravis disease. But there are some treatments such as medications and surgery for slows down the disease progression, management of the symptoms, and prevention of unnecessary complications.

Currently, researchers are majorly focused on understanding the specifics of the autoimmune problems related to MG and improving diagnosis methods and treatments. Moreover, other important area of research physiology of the neuromuscular junction (NMJ), is improving its function irrespective of probable immune system attacks.

Myasthenia Gravis Treatment Market Trends, Drivers, Restraints, and Opportunities

• Increasing research and development activities and growing number of clinical trials for treatment are anticipated to drive the market growth over the forecast period.
• Rising population with MG disease in emerging countries, growing geriatric population, and increasing cases of neuromuscular disorders are expected to boost the growth of the market.
• Increasing awareness about the treatment line among patients and growing number of clinical facilities are projected to propel the market growth.
• Side effects of drugs, high cost of treatment, and high dose combination results into severe muscle cramps are major factors that can impede the market growth.
• In Covid-19 pandemic situation researchers are focusing on Covid-19 research. Due to this other clinical trials and researches are reduced which hampered the growth of myasthenia gravis treatment market.

Scope of Myasthenia Gravis Treatment Market Report

The report on the global myasthenia gravis treatment market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Myasthenia Gravis Treatment Market Segment Insights

Medication segment is projected to hold a key market share

Based on treatments, the myasthenia gravis treatment market is divided into medication, surgery, and others. The medication segment is expected to hold a key share of the market during the forecast period. This is due to medications are dramatically constrain the immune system and majorly manages the associated symptoms. Medications include immunotherapies such as corticosteroids, Soliris (eculizumab), and immunosuppressive drugs includes Neoral/Sandimmune (cyclosporine) and Prograf (tacrolimus).

Surgery is other major treatment alternative which includes a thymectomy (thymus removal). It is invasive in nature. The thymus deteriorates with age (thymic involution), though complete loss of the thymus in a significant manner is expected to weaken a patient’s immune system.

Increasing number of pipeline R&D of drug development is projected to fuel the growth of the myasthenia gravis treatment market. Recently, the U.S. FDA and the European Commission, approved Alexion Pharmaceuticals’ Soliris (eculizumab) for treating adult myasthenia gravis patients who are anti-AchR antibody-positive. Soliris is a complement and first inhibitor for this disorder. The rising use of immunosuppressant and monoclonal antibodies is targeted the reduction of lifelong exposure to corticosteroids.

Get Free Sample Report

Clinic segment is expected to expand at a rapid pace

On the basis of end-users, the myasthenia gravis treatment market is segmented into hospitals, clinics, and others. The hospital segment is expected to hold a key share of the market during the forecast period. The growth of the segment is attributed to high demand of advanced equipment for myasthenia gravis treatment and huge patient pool. Number of patient visits for the MG treatment is increasing because of accessibility of such facilities. Moreover, rising investment in state-of-the-art healthcare infrastructures is one of the major driving factor.

On the other hand, the clinic segment is anticipated to expand at a rapid pace during the forecast period. Recently, need of specialized treatments is increasing also many patients are choosing specialty clinics for effective treatment and quick diagnosis. Furthermore, many end-users are dependent on e-commerce channel for treatment. Such segments are majorly boosting the growth of myasthenia gravis treatment market.

North America is anticipated to dominate the market

On the basis of regions, the myasthenia gravis treatment market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America hold largest market share and is expected to exhibit a rapid growth rate in the coming years. The regional market growth can be attributed to growing expenditure on healthcare, huge adoption of immunotherapies and monoclonal antibodies, favorable reimbursement scenario, and presence of established R&D facilities.

However, the market of Asia Pacific is anticipated to expand at an impressive CAGR during the forecast period owing to the growing generation of revenue through medications such as immunosuppressant and monoclonal antibodies in this region. Furthermore, initiatives taken by government and manufacturers for increasing investment is one of the boosting factor responsible for the regional growth.

Get Free Sample Report

Segments

The global myasthenia gravis treatment market has been segmented on the basis of

Treatments

• Medication
• Surgery
• Others

End-Users

• Hospitals
• Clinics
• Others

Regions

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• Alexion Pharmaceutical Inc.
• Grifols SA
• Avadel Pharmaceuticals plc.
• Novartis AG
• Pfizer Inc.
• AbbVie Inc.
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc.
• Bausch Health Companies Inc.
• Shire plc.

Competitive Landscape

Key players competing in the myasthenia gravis treatment market are Alexion Pharmaceutical Inc., Grifols SA, Avadel Pharmaceuticals plc., Novartis AG, Pfizer Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc., Bausch Health Companies Inc., and Shire plc.

Many key players are launching new products and constant innovation are driving the market growth. For instance, Argenx, in June 2020, introduced its awareness efforts for autoimmune disease myasthenia gravis. Also, major market players implement several other business strategies such as mergers, acquisitions, partnerships, collaborations, and capacity expansion to enhance their market shares.